Stratified Medicine Scotland Innovation Centre (SMS-IC) Projects

Stratified Medicine Scotland Innovation Centre (SMS-IC) Projects

Stratified Medicine Scotland Innovation Centre Exemplar project.

SMS-IC is a partnership comprising the Universities of Glasgow, Edinburgh, Dundee and Aberdeen; NHS Greater Glasgow and Clyde, NHS Grampian, NHS Lothian and NHS Tayside. Business partners involved in the SMS-IC are Biopta, Thermofisher Scientific, Aridhia informatics, Arrayjet, DestiNA Genomics, Fios Genomics and Sistemic. The Scottish Funding Council is providing £8m over five years to back the creation of the £20m SMS-IC at the new South Glasgow Hospitals Campus.

There are a number of Exemplar projects running in parallel and comprising different members of The SMS-IC. Biopta is leading an exemplar project focusing on irritable bowel syndrome (IBD) and chronic obstructive pulmonary disease (COPD).

It is well recognised that within a patient population wide variation in response to therapy can exist, an example is the effectiveness of bronchodilators in the treatment of asthma. Biopta has been able to demonstrate this variation in functional assays using fresh human tissue.


The IBD & COPD Exemplar project will utilise fresh human tissue ex vivo assays to correlate disease phenotype with genotype and the aim is to identify potential genetic signatures that may aid personalised medicine. The development of these functional assays and the correlation with genotype may better predict how a patient will respond to a particular drug or line of therapy at an early stage of preclinical development.


For more information on The SMS-IC please visit:


An Investigation into the Influence of Disease Drive on the Efficacy of Antihypertensive Medications. MSc Stratified Medicine Research Project, Hazel Simpson

Hypertension affects a vast proportion of the global population and is linked to the development of further cardiovascular disorders.  It is also well known as a condition where patients frequently do not respond adequately to initial therapeutic interventions.    

It is often assumed that stratification of patient treatment will centre on analysis of the genetic drivers of a patients disease, however, this is not the only means by which a general disease classification may be subdivided.  Inter-individual differences exist in both the underlying levels of disease drive and in pharmacokinetic activity. Investigating how these factors alter the efficacy of pharmacological interventions may provide further insight into how to successfully treat uncontrolled hypertension and guide alterations to the current manner of treatment allocation.  This may be a change in dosage or a change in drug where the required dose exceeds that deemed safe by the therapeutic index.  In the long run, developing new strategies to aid the assignation of anti-hypertensive therapies could have a significant impact on mortality relating to cardiovascular disease.

Live chat by BoldChat